Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 7, 2008

Catalyst and Centocor Ink Agreement Related to Engineered Protease Treatments

  • Catalyst Biosciences will use its Alterase™ therapeutics in an exclusive, worldwide research and license agreement with Centocor Research & Development. Alterase therapeutics are protease biologics engineered with the ability to catalytically cleave and inactivate disease-causing proteins.

    Under terms of the collaboration, Centocor will support Catalyst’s discovery research and preclinical development of Alterase drug candidates against two targets, one of them inflammatory disease. Centocor may expand the agreement to include a third target.

    Catalyst Biosciences will receive an upfront payment of $11 million, which includes both cash and an equity investment by Johnson & Johnson. They will also obtain additional research funding for two years.

    Centocor will be responsible for all development, manufacturing, and commercialization efforts associated with the Alterase products discovered through the collaboration in exchange for future milestones and royalties.



Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »